Tadalafil (Generic) Complete Drug-Drug Interaction Profile

Generic tadalafil works as a phosphodiesterase type 5 (PDE5) inhibitor and comes in tablet doses ranging from 2.5 mg to 20 mg, offering a more affordable alternative to the brand-name Cialis. The FDA has approved tadalafil for treating erectile dysfunction with flexible dosing schedules (as-needed or continuous daily use), managing benign prostatic hyperplasia (BPH) symptoms affecting the lower urinary tract (usually taken daily at 5 mg), and pulmonary arterial hypertension under the separate brand Adcirca. The drug interactions discussed here apply specifically to generic tadalafil when used for erectile dysfunction or benign prostatic hyperplasia with lower urinary tract symptoms. This information should not replace consulting the most recent FDA-approved product labeling or speaking with a pharmacist about how generic tadalafil interacts with your complete list of medications.

The core fact a reader needs: tadalafil is absolutely contraindicated with organic nitrates and with riociguat because both combinations can cause severe, unpredictable drops in blood pressure through additive nitric oxide-cGMP pathway effects; strong CYP3A4 inhibitors (such as ketoconazole, itraconazole, or ritonavir-boosted antiretrovirals) require the FDA-labeled dose ceiling of no more than 10 mg once every 72 hours for on-demand use; and alpha-blockers require careful initiation and dose separation because of additive blood-pressure lowering, not metabolic interference. Everything else in tadalafil's interaction profile is a matter of degree, not an absolute stop.

Why tadalafil's interaction window is longer than other PDE5 inhibitors

Tadalafil's labeled elimination half-life is approximately 17.5 hours, several times longer than sildenafil's (roughly 3-5 hours) or vardenafil's (roughly 4-5 hours). This matters because any pharmacodynamic interaction, especially blood pressure lowering, persists in the body far longer with tadalafil than with shorter-acting PDE5 inhibitors. It is the reason the nitrate washout period after tadalafil (48 hours) is longer than after sildenafil (24 hours).

Tadalafil is metabolized mainly by the CYP3A4 enzyme in the liver. Drugs that strongly inhibit or induce CYP3A4 raise or lower tadalafil blood levels in a fairly predictable direction, even though the exact magnitude reported in older pharmacokinetic studies should be checked against the current FDA label rather than treated as fixed. Tadalafil is a substrate of CYP3A4 but does not meaningfully inhibit it, so tadalafil is generally not expected to raise the levels of other CYP3A4 substrates.

Absolute contraindications: nitrates and riociguat

Two categories have no safe dose, timing workaround, or monitoring strategy that makes co-administration acceptable.

Organic nitrates (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, amyl nitrite) combined with any PDE5 inhibitor can produce a synergistic, severe drop in blood pressure through combined effects on the nitric oxide-cGMP pathway. Because of tadalafil's long half-life, the FDA labeling and clinical guidance describe a required nitrate-free window of at least 48 hours after the last tadalafil dose, longer than the corresponding window for shorter-acting PDE5 inhibitors. If a patient on tadalafil needs nitrate therapy for acute chest pain, this washout period should be treated as a hard rule, and clinicians should use alternative anti-anginal measures during the interval. The current FDA prescribing information for Cialis (tadalafil) describes this contraindication language, and readers should verify the exact wording against the most recent label update.

Riociguat (Adempas), a soluble guanylate cyclase stimulator used for pulmonary hypertension, amplifies the same nitric oxide-cGMP pathway through a distinct mechanism that is additive with PDE5 inhibition. The Adempas prescribing information lists PDE5 inhibitors, including tadalafil, as contraindicated because of symptomatic hypotension risk (label current as of its 2013 approval; verify current status).

Strong and moderate CYP3A4 inhibitors: dose ceilings, not automatic avoidance

Drugs that strongly inhibit CYP3A4, including ketoconazole, itraconazole, clarithromycin, and ritonavir- or cobicistat-boosted HIV regimens (for example, Stribild, Genvoya, Prezcobix), raise tadalafil blood levels substantially. Older pharmacokinetic studies describe large percentage increases in tadalafil exposure with agents like ketoconazole and ritonavir; the exact fold-change figures vary by study and should be verified against current labeling rather than quoted as a fixed number.

The FDA-labeled approach for co-prescribing a strong CYP3A4 inhibitor with tadalafil is:

• On-demand use: a maximum tadalafil dose of 10 mg, no more often than once every 72 hours.
• Daily use (ED or BPH-LUTS): a reduced daily dose, generally down to 2.5 mg, with consideration of avoiding daily tadalafil altogether if the inhibitor is used chronically.

Moderate CYP3A4 inhibitors, including erythromycin, fluconazole, verapamil, and diltiazem, are expected to raise tadalafil exposure to a lesser degree. The FDA label does not mandate a fixed dose cap for moderate inhibitors, but starting at the lower end of the dosing range and watching for hypotensive symptoms is a reasonable, evidence-consistent approach even without a dedicated per-drug study for every combination.

Grapefruit juice is a weak-to-moderate CYP3A4 inhibitor. Occasional consumption is unlikely to matter clinically; habitual high-volume intake could plausibly raise tadalafil levels modestly, though this has not been rigorously quantified for tadalafil specifically.

CYP3A4 inducers: an underrecognized cause of treatment failure

Strong CYP3A4 inducers, including rifampin, phenytoin, carbamazepine, phenobarbital, and St. John's wort, can lower tadalafil blood levels enough to cause a meaningful loss of effect. Rifampin's effect on tadalafil exposure has been described in pharmacokinetic literature as large enough that increasing the tadalafil dose within the approved range would not reliably restore efficacy; this specific finding should be confirmed against the current label or a pharmacist reference before being treated as an exact number, but the direction and clinical implication (possible therapeutic failure) is well established for strong inducers as a class.

St. John's wort is worth flagging specifically because patients often do not volunteer supplement use during medication review, and an unexplained loss of tadalafil effectiveness is a reasonable trigger to ask about it directly.

Tadalafil Interaction Risk-Tiering Decision Rule

This is a practical triage framework for a prescriber or pharmacist screening a tadalafil prescription against a patient's other medications. It does not replace an individualized interaction check, and it does not set a dose for any specific patient.

Tier 1: Stop. Do not co-prescribe under any circumstance.

• Any organic nitrate (nitroglycerin, isosorbide mono/dinitrate, amyl nitrite/"poppers") within 48 hours of a tadalafil dose.
• Riociguat, at any time, regardless of tadalafil dose or timing.
• Action: do not fill or dispense together; if a nitrate is needed urgently for a patient on tadalafil, use non-nitrate anti-anginal measures and observe the 48-hour washout.

Tier 2: Proceed only with a labeled dose cap.

• Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir- or cobicistat-boosted antiretrovirals, idelalisib and similar strong-inhibitor oncology agents).
• Action: cap on-demand tadalafil at 10 mg no more than every 72 hours; reduce or avoid daily dosing; document the reason for the reduced dose in the chart.

Tier 3: Proceed with monitoring, no automatic dose cap.

• Alpha-blockers (see below), multi-drug antihypertensive regimens, moderate CYP3A4 inhibitors, heavy alcohol use, low baseline blood pressure, or volume depletion from diuretics.
• Action: start at the lower end of the tadalafil dosing range, check orthostatic vital signs at the first dose if risk factors stack up, and counsel on dizziness symptoms.

Tier 4: Watch for reduced effectiveness, not toxicity.

• Strong or moderate CYP3A4 inducers (rifampin, anticonvulsants, St. John's wort, efavirenz, chronic dexamethasone).
• Action: ask directly about supplement and antiretroviral use if tadalafil seems ineffective; do not simply escalate the dose past the labeled maximum without reassessing the interacting drug.

Tier 5: No dose adjustment needed based on available evidence.

• Warfarin, aspirin/NSAIDs, metformin/insulin, standard-dose statins, antacids, theophylline, metoprolol at studied doses.
• Action: no routine dose change; still document the combination.

Use this only as a first-pass sort. A patient with several Tier 3 factors stacked together (for example, an alpha-blocker plus three antihypertensives plus low baseline blood pressure) should be treated more cautiously than the individual tiers suggest in isolation.

Alpha-blockers: additive blood pressure lowering, not a metabolic interaction

Alpha-adrenergic blockers used for BPH or hypertension interact with tadalafil through additive vasodilation, not through CYP3A4. The concern is orthostatic hypotension, particularly with the first doses.

Tamsulosin, a uroselective alpha-1A blocker, has shown minimal blood pressure interaction with tadalafil in controlled studies and is generally considered the preferred alpha-blocker to combine with tadalafil, still with a dosing separation of several hours as a precaution. Doxazosin, a non-selective alpha-blocker, has produced clinically meaningful blood pressure drops in combination with tadalafil in controlled studies, including standing systolic drops large enough to cause symptoms in some individuals. When both drugs are clinically necessary, a common approach is to stabilize the patient on the alpha-blocker first, start tadalafil at the lowest dose, and separate dosing by several hours, consistent with urology guidance on PDE5 inhibitor and alpha-blocker co-administration. Alfuzosin appears to fall between tamsulosin and doxazosin in interaction risk; silodosin, also uroselective, appears to behave more like tamsulosin, though published co-administration data for silodosin specifically are limited.

Patients already taking daily low-dose tadalafil for combined ED and BPH-LUTS (an FDA-approved use) generally do not need a separate alpha-blocker added purely for LUTS, since tadalafil itself has demonstrated benefit for BPH symptoms in clinical trials, though exact symptom-score improvements vary by study and population and should not be quoted as a guaranteed individual result.

Antihypertensives and alcohol: additive, generally manageable

Tadalafil produces a small blood pressure reduction on its own. Layered onto antihypertensive therapy, the additive effect has generally been modest (roughly a few mmHg) in studied combinations with ACE inhibitors, ARBs, amlodipine, and beta-blockers, and does not typically require a dose change of either drug for a patient on a single antihypertensive. Diuretics have not been as thoroughly studied in combination with tadalafil, and patients with volume depletion or marginal blood pressure on loop or thiazide diuretics warrant closer symptom monitoring after starting tadalafil rather than a specific pre-set dose adjustment. Patients on three or more antihypertensive agents are reasonable candidates for a more conservative starting tadalafil dose with observed first-dose response.

Alcohol interacts with tadalafil through an additive pharmacodynamic effect on blood vessels, not through CYP3A4 metabolism. Heavier acute alcohol intake combined with tadalafil has been associated with a measurable additional drop in standing blood pressure in controlled studies; moderate drinking (one to two standard drinks) has not shown a clinically detectable interaction in the available data. The practical guidance is that occasional moderate drinking does not require a tadalafil dose change, while heavy drinking, especially in someone also taking blood pressure medication, raises the risk of symptomatic dizziness.

Combinations with no established clinically significant interaction

Several commonly co-prescribed drugs have been studied and have not shown a meaningful interaction with tadalafil. This list matters because it helps avoid unnecessary discontinuations: warfarin (no change in INR or prothrombin time in stabilized patients), aspirin and NSAIDs (no effect on bleeding time or platelet aggregation), antacids (no effect on tadalafil absorption), theophylline, metformin and insulin, and statins such as atorvastatin and lovastatin (both are CYP3A4 substrates but do not compete meaningfully with tadalafil for clearance at therapeutic doses). Midazolam studies support that tadalafil does not meaningfully inhibit CYP3A4 itself, which is the basis for expecting tadalafil not to raise levels of other CYP3A4-cleared drugs.

Special populations that need extra attention

HIV-positive patients on antiretroviral therapy. Protease inhibitors and cobicistat-containing regimens act as strong CYP3A4 inhibitors, so the same Tier 2 dose cap applies: a maximum of 10 mg tadalafil no more than once every 72 hours for on-demand use. Efavirenz, by contrast, is a CYP3A4 inducer and may reduce tadalafil's effect, which can prompt titration toward the higher end of the approved dose range under clinician guidance. Current HIV treatment guidelines from the Department of Health and Human Services, hosted via the National Institutes of Health, address antiretroviral drug interactions generally; a reader or clinician needing the exact current PDE5-inhibitor dosing table should confirm it directly in the current guideline document rather than relying on any secondhand summary, including this one.

Transplant recipients on calcineurin inhibitors. Cyclosporine and tacrolimus are CYP3A4 substrates with some inhibitory activity. Dedicated tadalafil interaction data for this population are limited, so a cautious starting dose (5 mg on-demand) with monitoring is a reasonable, conservative approach rather than a guideline-based rule.

Oncology patients on targeted therapies. Certain kinase inhibitors are strong or moderate CYP3A4 inhibitors. Where a strong inhibitor is involved, the same Tier 2 dose-cap logic used for ketoconazole or ritonavir applies.

What is established, what is plausible, and what is not established

Established, with regulatory backing: the nitrate and riociguat contraindications, the direction of CYP3A4 inhibitor and inducer effects on tadalafil levels, and the FDA-labeled dose ceiling for use with strong CYP3A4 inhibitors.

Plausible but not rigorously quantified for tadalafil specifically: the exact percentage increase or decrease in tadalafil exposure from many individual moderate inhibitors and inducers, grapefruit juice's real-world effect size, and calcineurin-inhibitor interaction magnitude in transplant patients.

Not established from the material available for this article: precise numeric percentage changes in tadalafil AUC for several agents cited in older secondary summaries. Anyone who needs an exact fold-change number for a clinical or regulatory decision should pull it directly from the current FDA label or a primary pharmacokinetic study rather than from this or any other secondary article.

Monitoring: what actually changes management

Blood pressure, not a blood level, is the practical thing to track. Checking seated and standing blood pressure before and roughly two hours after a first tadalafil dose is useful when adding any new vasoactive medication, especially an alpha-blocker or a strong CYP3A4 inhibitor. There is no commercially available or clinically indicated blood test for monitoring tadalafil levels.

Three symptom categories deserve immediate attention regardless of what else is happening: lightheadedness on standing, sudden vision changes (including the rare but serious non-arteritic anterior ischemic optic neuropathy), and an erection lasting more than 4 hours (priapism), which is a urologic emergency. Any of these warrants stopping and reassessing the full medication list, including over-the-counter supplements and recreational substances such as amyl nitrite ("poppers"), which patients do not reliably disclose unless asked directly.